Effect of IL6 -174 G/C Gene Polymorphism on Response to Interleukin-6 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis
DOI:
https://doi.org/10.12970/2310-9874.2022.10.01Keywords:
Interleukin 6, Systemic Idiopathic Arthritis, Interleukin-6 blockade therapy, IL6 gene polymorphismsAbstract
Objective: The main objective of this study was to evaluate the association of IL6-174 G/C gene polymorphisms and the response to tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (s-JIA).
Methods: Sixty patients with s-JIA (37 males and 23 females with median age at onset of 5.2 years) who received TCZ were recruited. Basic demographic, laboratory and clinical data were collected alongside the IL-6 haplotype status. The overall response to treatment with TCZ was assessed according to a number of variables including the extent of disease activity reduction, the achievement of clinically inactive disease, the necessity to switch to another biologic disease modifying anti-rheumatic drug (bDMARD) and the achievement of a glucocorticoid-free state.
Results: Three IL6 -174 genotypes, including, GG, GC, and CC were found with higher frequencies of GC genotype. These genotypes had non-significant association with the response of s-JIA patients to IL-6 blockade in this cohort study. However, a longer time frame from disease onset to diagnosis was associated with poorer long-term treatment response.
Conclusion: We observed no significant impact of IL6 -174 G/C gene polymorphisms on treatment response to TCZ in s-JIA Egyptian patients. The observation that a shorted timeframe between symptom onset and diagnosis is associated with better long-term response to TCZ provides evidence for a therapeutic “window of opportunity” in patients with s-JIA.
References
Symmons D, Jones M, Osborne J, Sills J, Southwood T, Woo P. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheum1996; 11: 13-16.
Laxer R, Schneider R. Systemic-onset juvenile chronic rheumatoid arthritis and adult-onset Still’s disease. In Oxford Textbook of Rheumatology. Maddison P, Isenberg D, Woo P, Glass D, Eds. Oxford Medical Publications, Oxford 1993; 722-731.
Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am 1991; 17: 891-905. https://doi.org/10.1016/S0889-857X(21)00134-4
Fishman D, Rooney M, Woo P. Successful management of reactive haemophagocytic syndrome in systemic-onset juvenile chronic arthritis. Br J Rheumatol 1995; 34: 888. https://doi.org/10.1093/rheumatology/34.9.888
De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34: 1158-1163.
Lepore L, Pennesi M, Saletta S, Perticarari S, Presani G, Prodan M. Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994; 12: 561-565. https://doi.org/10.1002/art.1780340912
Mangge H, Kenzian H, Gallistl S, Neuwirth G, Liebmann P, Kaulfersch W, Beaufort F, Muntean W, Schauenstein K. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995; 38: 211-220. https://doi.org/10.1002/art.1780380209
De Benedetti F, Pignatti P, Massa M, Sartirana P, Ravelli A, Martini A. Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1995; 13: 779-784.
Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16: 448-57. https://doi.org/10.1038/ni.3153
McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheuatoid arthritis - shaping the immunological landscape. Nat Rev Rheumatol 2016; 12: 63-8. https://doi.org/10.1038/nrrheum.2015.171
Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care 2012; 18(13 Suppl): S295-302.
Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374(Pt 1): 1-20. https://doi.org/10.1042/bj20030407
Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121: 3375-83. https://doi.org/10.1172/JCI57158
Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 818-825. https://doi.org/10.1002/art.20944
Wolford JK, Bcolligan P, Gruber JD, Bogardus C. Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians Metabolism 2011; 60(10): 1488-1496.
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton. J Rheumatol 2001; 31: 390-2.
Bielak M, Husmann E, Weyandt N, Haas JP, Hügle B, Horneff G, et al. IL-6 blockade in systemic juvenile idiopathic arthritis— achievement of inactive disease and remission (data from the German AID-registry). Pediatr Rheumatol Online J 2018; 16: 22. https://doi.org/10.1186/s12969-018-0236-y
Arthur VL, Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, et al. IL1RN variation influences both disease susceptibility and response to recombinant human interleukin-1 receptor antagonist therapy in systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2018; 70: 1319-30. https://doi.org/10.1002/art.40498
Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N, for the Childhood Arthritis and Rheumatology Research Alliance (CARRA), Pediatric Rheumatology Collaborative Study Group (PRCSG), Paediatric Rheumatology International Trials Organisation (PRINTO). American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011; 63: 929-36. https://doi.org/10.1002/acr.20497
Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. for the Paediatric Rheumatology International Trials Organisation. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658-66. https://doi.org/10.1002/art.24516
Revillaa M, Obacha V, Cerveraa A, Davalosb A, Castilloc J, Chamorroa A. A -174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. J Neuroscience Letters 2002; 324: 29-32. https://doi.org/10.1016/S0304-3940(02)00169-6
Luxembourger C, Ruyssen-Witrand A, Ladhari C, Rittore C, Degboe Y, et al. A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients. Pharmacogenomics J 2019; 19(4): 368-374. https://doi.org/10.1038/s41397-019-0072-6
Maldonado-Montoro M, Cañadas-Garre M, González-Utrilla A, Ángel Calleja-Hernández Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis. Pharmacogenomics J 2018; 18(1): 167-172. https://doi.org/10.1038/tpj.2016.88
Ogilvie EM, Fife MS, Thompson SD, Twine N, Tsoras M, Moroldo M, Fisher SA. The -174G Allele of the Interleukine-6 Gene Confers Susceptibility to Systemic Arthritis in Children. A Multicenter Study Using Simplex and Multiplex Juvenile Idiopathic Arthritis Families. Arthritis and Rheumatism 2003; 48(11): 3202-3206. https://doi.org/10.1002/art.11300
Ceccarelli F, Perricone C, Fabris M. Transforming growth factor β 869 C /T and interleukin-6 -174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritis. Arthritis Res Ther 2011; 13(4): R1-11. https://doi.org/10.1186/ar3396
Murray K, Donnelly P, Passo M, Giannini E, Glass D. Windows of effect of disease associated HLA alleles in juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: S2-41.
Al-Harbi SJ, Hadi MA, Rashid KH. Association of IL-6 gene−174 G/C (rs1800795) Polymorphism with Juvenile Idiopathic Arthritis in Iraqi Patients. Indian Journal of Forensic Medicine & Toxicology, October-December 2019; 13(4). https://doi.org/10.5958/0973-9130.2019.00397.9
Kishimoto T. Interleukin-6: from basic science to medicine: 40 years in immunology. Annu Rev Immunol 2005; 23: 1-21. https://doi.org/10.1146/annurev.immunol.23.021704.115806
Hinze C, Fuehner S, Kessel C, Wittkowski H, Lainka E, et al. Impact of IL1RN Variants on Response to Interleukin-1Blocking Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis & Rheumatology 2020; 72(3): 499-505. https://doi.org/10.1002/art.41130
Yokota S, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52(3): 818-825. https://doi.org/10.1002/art.20944
Woo P, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7(6): R1281-R1288.
Nigrovic PA. Is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? [review]. Arthritis Rheumatol 2014; 66: 1405-13. https://doi.org/10.1002/art.38615
Pascual V, Allantaz F, Arce E, Punaro M, Banchereaux J. Role of interleukin (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86. https://doi.org/10.1084/jem.20050473
Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355-9. https://doi.org/10.1084/jem.20050640
De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34: 1158-63. https://doi.org/10.1002/art.1780340912
Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-76. https://doi.org/10.1172/JCI2629
Ogilvie EM, Fife MS, Thompson SD, et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children. Arthritis Rheum 2003; 48: 3202-6. https://doi.org/10.1002/art.11300
Artsymovych A, Oshlianska O, Rossokha Z. Allelic polymorphism of proinflammatory cytokine genes as a basis for the formation of phenotypes of juvenile idiopathic arthritis. Abstract in; Basic and translat. scien. in paediat. Rheum.AB0173.Annals of rheum.dis, 1136, 2020 eular 2300, 79(suppl.1). https://doi.org/10.1136/annrheumdis-2020-eular.2300
Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901. https://doi.org/10.1016/S0092-8674(00)80801-6
Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37. https://doi.org/10.1189/jlb.0306170
Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta(2) integrin Mac-1 on neutrophils. J Immunol 1998; 160: 1427-35.
